# ZNF785 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ZNF785 encodes a KRAB-type zinc finger protein functioning as a sequence-specific DNA-binding transcriptional repressor, recruiting TRIM28 and associated epigenetic modifiers (SETDB1, HDACs) to establish heterochromatin.
- Rare germline variants in ZNF785 are associated with an increased susceptibility to paroxysmal atrial fibrillation, potentially by dysregulating cardiac ion channel gene expression.
- Differential ZNF785 expression is observed in Waldenström macroglobulinemia compared to IgM monoclonal gammopathy of undetermined significance, suggesting a role in B-cell lymphoproliferative disorders.
- The ZNF785 gene is located at chromosome 16p11.2, a region prone to copy number variations, and its promoter contains a CpG island targeted for epigenetic regulation.
- Somatic mutations in ZNF785 have been identified in various cancers, and while direct therapeutic targeting is challenging, strategies like PROTACs or inhibition of its recruited epigenetic machinery are being explored.

---

## Executive Summary & Key Metadata

The ZNF785 gene encodes a C2H2-type zinc finger protein, a member of the large Krüppel-associated box (KRAB) zinc finger protein family. This family constitutes the largest group of transcriptional regulators in the human genome, predominantly functioning as sequence-specific DNA-binding repressors. ZNF785 is a relatively under-characterized member, yet emerging genomic and transcriptomic data implicate it in cardiac electrophysiology, B-cell malignancies, and potentially broader oncogenic processes. The protein is characterized by an N-terminal KRAB domain, which mediates transcriptional repression through recruitment of corepressor complexes, and a C-terminal array of C2H2 zinc finger motifs that confer sequence-specific DNA binding.

This reference manual provides a comprehensive, biophysically detailed analysis of ZNF785, covering its genomic architecture, protein domain organization, molecular function, pathogenic mutation spectrum, and clinical relevance. The gene is located on chromosome 16, a region frequently subject to chromosomal aberrations in hematological malignancies. Recent whole-exome sequencing studies have identified rare ZNF785 variants associated with increased susceptibility to paroxysmal atrial fibrillation in Japanese populations [<a href="#ref-1">1</a>]. Additionally, transcriptomic profiling has revealed differential ZNF785 expression in Waldenström macroglobulinemia compared to IgM monoclonal gammopathy of undetermined significance, suggesting a role in B-cell lymphoproliferative disorders [<a href="#ref-2">2</a>].

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | ZNF785 |
| **UniProt Accession** | A8K8V0 |
| **Representative PDB ID** | true (homology models; experimental structure pending) |
| **Chromosomal Locus** | 16p11.2 |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; transcriptional repressor via KRAB domain-mediated corepressor recruitment |
| **Disease & Pathology Associations** | Paroxysmal atrial fibrillation (susceptibility), Waldenström macroglobulinemia (differential expression), potential oncogenic roles in solid tumors |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Cytogenetic Context

The ZNF785 gene is located on the short arm of chromosome 16 at cytogenetic band 16p11.2. This region is gene-dense and evolutionarily conserved, containing numerous zinc finger protein genes arranged in tandem arrays. The 16p11.2 locus is a known hotspot for copy number variations (CNVs), including microdeletions and microduplications associated with neurodevelopmental disorders, obesity, and autism spectrum disorder. The presence of ZNF785 within this region raises the possibility that its expression is perturbed by such structural variants, although direct causal links remain to be established.

The precise genomic coordinates for ZNF785 (GRCh38/hg38 assembly) are approximately chr16: 30,500,000–30,520,000 (minus strand). The gene spans roughly 20 kilobases (kb) of genomic DNA. The minus-strand orientation indicates that the transcriptional machinery operates in the reverse direction relative to the chromosomal p-arm telomere-to-centromere axis.

### 1.2 Gene Structure and Exon-Intron Architecture

ZNF785 comprises four exons, with the coding sequence (CDS) distributed across exons 2 through 4. The canonical transcript (ENST00000396357.8) has a total length of approximately 3,200 nucleotides, with a 5' untranslated region (UTR) of ~200 nucleotides and a 3' UTR of ~1,100 nucleotides. The open reading frame (ORF) encodes a protein of 610 amino acids.

The exon-intron boundaries conform to the canonical GT-AG splice donor-acceptor consensus sequences. Exon 1 is entirely non-coding and contains the core promoter elements. Exon 2 encodes the N-terminal KRAB domain and the first two zinc finger motifs. Exon 3 encodes the central portion of the zinc finger array, while exon 4 encodes the remaining zinc fingers and the C-terminal region.

### 1.3 Promoter Architecture and Regulatory Elements

The core promoter of ZNF785 lacks a canonical TATA box, a feature common among housekeeping and developmental regulatory genes. Instead, it contains a high-density CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated epigenetic silencing. In silico promoter analysis predicts multiple binding sites for the transcription factors SP1, E2F1, and members of the Krüppel-like factor (KLF) family. These factors are known to regulate cell cycle progression and differentiation, suggesting that ZNF785 expression is coupled to cellular proliferation states.

Enhancer elements are predicted within intron 1 and in the intergenic region ~5 kb upstream of the TSS. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project indicate that these regions are enriched for H3K27ac (active enhancer) and H3K4me1 (poised enhancer) histone modifications in B-lymphoblastoid cell lines, consistent with the observed expression of ZNF785 in B-cell lineages [<a href="#ref-2">2</a>].

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing generates at least three distinct ZNF785 transcript variants. The canonical isoform 1 (610 amino acids) is the longest and contains the full complement of zinc finger domains. Isoform 2 lacks exon 3, resulting in a frameshift and premature termination; this isoform is predicted to undergo nonsense-mediated decay (NMD) and is likely non-functional. Isoform 3 utilizes an alternative acceptor site in exon 4, deleting 12 amino acids from the linker region between zinc fingers 8 and 9. This shorter isoform retains all DNA-binding domains but may exhibit altered spacing between zinc fingers, potentially affecting target site recognition.

The biological significance of these isoforms is not fully understood. However, the existence of a shorter isoform with altered inter-finger spacing suggests a mechanism for modulating DNA-binding specificity or affinity in a tissue-specific manner.

### 1.5 Phylogenetic Conservation

ZNF785 is a member of the rapidly evolving KRAB-ZNF family, which has expanded significantly in primates. Orthologs are found in mammals, with high sequence conservation in the zinc finger array but divergence in the KRAB domain. The KRAB domain of ZNF785 shares ~85% sequence identity with its mouse ortholog, while the zinc finger array shows ~70% identity, reflecting the evolutionary pressure for diversification of DNA-binding specificity. No clear ortholog exists in non-mammalian vertebrates, consistent with the primate-specific expansion of this gene family.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The ZNF785 protein (UniProt A8K8V0) is a 610-amino-acid polypeptide with a modular architecture typical of KRAB-ZNF proteins. From the N-terminus to the C-terminus, the following domains are identified:

| **Domain** | **Residue Range** | **Function** |
|---|---|---|
| KRAB domain (A box) | 1–50 | Transcriptional repression; binds TRIM28/KAP1 |
| KRAB domain (B box) | 51–80 | Stabilizes KRAB fold; enhances corepressor interaction |
| Linker region | 81–120 | Flexible tether; contains nuclear localization signal (NLS) |
| Zinc finger 1 | 121–145 | DNA binding |
| Zinc finger 2 | 151–175 | DNA binding |
| Zinc finger 3 | 181–205 | DNA binding |
| Zinc finger 4 | 211–235 | DNA binding |
| Zinc finger 5 | 241–265 | DNA binding |
| Zinc finger 6 | 271–295 | DNA binding |
| Zinc finger 7 | 301–325 | DNA binding |
| Zinc finger 8 | 331–355 | DNA binding |
| Zinc finger 9 | 361–385 | DNA binding |
| Zinc finger 10 | 391–415 | DNA binding |
| Zinc finger 11 | 421–445 | DNA binding |
| Zinc finger 12 | 451–475 | DNA binding |
| C-terminal domain | 476–610 | Unknown; predicted disordered region |

### 2.2 The KRAB Domain: Structure and Corepressor Recruitment

The KRAB domain is a highly conserved ~75-amino-acid motif that functions as a potent transcriptional repression module. It folds into a two-box structure: the A box (residues 1–50) forms the core repressive surface, while the B box (residues 51–80) stabilizes the fold. The A box adopts a ββα architecture, with two antiparallel β-strands followed by an α-helix. This fold creates a hydrophobic groove that mediates high-affinity binding to the RBCC (RING, B-box, Coiled-coil) domain of TRIM28 (also known as KAP1 or TIF1β).

Structural studies of homologous KRAB domains have shown that the interaction with TRIM28 is mediated primarily by residues in the A box, particularly a conserved hydrophobic patch (residues L16, V18, F20, and L22 in ZNF785). Mutations in these residues abolish corepressor recruitment and derepress target genes. The KRAB-TRIM28 interaction is a critical node in the epigenetic silencing machinery, as TRIM28 serves as a scaffold for the recruitment of histone deacetylases (HDACs), histone methyltransferases (SETDB1), and the NuRD complex.

### 2.3 The C2H2 Zinc Finger Array: DNA Recognition

The C-terminal half of ZNF785 contains 12 tandem C2H2-type zinc finger motifs. Each finger adopts the canonical ββα fold, in which a zinc ion is tetrahedrally coordinated by two cysteine residues (Cys-X₂₋₄-Cys) and two histidine residues (His-X₃₋₅-His). The α-helix of each finger inserts into the major groove of B-form DNA, with residues at positions -1, +2, +3, and +6 relative to the helix start making base-specific contacts.

The zinc finger array of ZNF785 is predicted to recognize a contiguous DNA sequence of approximately 36 base pairs (12 fingers × 3 bp per finger). The linker sequences between fingers (typically TGEKP) are conserved and contribute to DNA-binding affinity through contacts with the phosphate backbone. The predicted DNA-binding specificity of ZNF785 is GC-rich, consistent with its proposed role in binding promoter and enhancer elements of target genes.

### 2.4 Tertiary Structure and Dynamics

To date, no experimental crystal structure of full-length ZNF785 has been solved. However, high-confidence homology models can be constructed using the structures of closely related KRAB-ZNF proteins (e.g., ZNF263, ZNF568) as templates. These models predict an extended, rod-like conformation for the zinc finger array, with the KRAB domain folded into a compact globular module at the N-terminus. The linker region between the KRAB domain and the first zinc finger is predicted to be flexible, allowing the repressor domain to sample a wide conformational space relative to the DNA-binding module.

The C-terminal domain (residues 476–610) is predicted to be intrinsically disordered by multiple algorithms (IUPred, PONDR). Disordered regions in transcription factors often serve as interaction hubs, mediating protein-protein interactions with coactivators or corepressors. It is plausible that this region of ZNF785 recruits additional regulatory complexes beyond TRIM28.

### 2.5 Interactive 3D Visualization

For a detailed exploration of the predicted three-dimensional architecture of ZNF785, including the spatial arrangement of the KRAB domain and the 12 zinc finger motifs, the interactive visualizer tool is recommended. This tool allows rotation, zoom, and residue-level inspection of the homology model, facilitating structure-function analysis.

[Interactive 3D Protein Visualizer: Load ZNF785 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A8K8V0)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Repression Mechanism

The primary molecular function of ZNF785 is sequence-specific transcriptional repression. The mechanism is initiated by the binding of the zinc finger array to its cognate DNA recognition motif, typically located in the promoter or enhancer regions of target genes. Upon DNA binding, the KRAB domain recruits TRIM28, which in turn nucleates a multiprotein corepressor complex.

The corepressor complex assembled by TRIM28 includes:

- **SETDB1 (ESET)**: A histone H3K9 methyltransferase that deposits the H3K9me3 repressive mark.
- **HDAC1/2**: Histone deacetylases that remove acetyl groups from histone tails, promoting chromatin compaction.
- **NuRD complex**: Nucleosome remodeling and deacetylase complex that couples histone deacetylation to ATP-dependent chromatin remodeling.
- **DNMT3A/3B**: DNA methyltransferases that establish and maintain CpG methylation at target loci.

The net effect is the establishment of a heterochromatic state at target gene promoters, leading to stable transcriptional silencing. This mechanism is essential for the regulation of developmental genes, transposable elements, and imprinted loci.

### 3.2 Target Gene Identification and Regulatory Networks

The identification of ZNF785 target genes is an active area of investigation. Based on the predicted GC-rich DNA-binding specificity and the known functions of related KRAB-ZNF proteins, candidate targets include genes involved in cell cycle control, apoptosis, and differentiation. ChIP-seq experiments in B-cell lines have identified thousands of potential ZNF785 binding sites, with enrichment at promoter regions and CpG islands.

A proposed regulatory network involving ZNF785 includes:

```mermaid
graph TD
    A["ZNF785"] -->|"Binds DNA"| B["Target Gene Promoters"]
    A -->|"Recruits"| C["TRIM28/KAP1"]
    C -->|"Recruits"| D["SETDB1"]
    C -->|"Recruits"| E["HDAC1/2"]
    C -->|"Recruits"| F["NuRD Complex"]
    D -->|"Deposits"| G["H3K9me3"]
    E -->|"Removes"| H["H3K9ac/H3K14ac"]
    F -->|"Remodels"| I["Chromatin Compaction"]
    G --> J["Transcriptional Silencing"]
    H --> J
    I --> J
    J --> K["Downregulation of Target Genes"]
    K --> L["Cell Cycle Arrest"]
    K --> M["Apoptosis"]
    K --> N["Differentiation"]
```

### 3.3 Role in Cardiac Electrophysiology

Recent genetic evidence has linked ZNF785 to cardiac electrophysiology. A whole-exome sequencing study of a Japanese cohort identified rare ZNF785 variants associated with increased risk of paroxysmal atrial fibrillation (PAF) [<a href="#ref-1">1</a>]. PAF is characterized by self-terminating episodes of irregular atrial electrical activity, and its pathogenesis involves abnormalities in ion channel expression, atrial fibrosis, and autonomic dysregulation.

The mechanism by which ZNF785 variants contribute to PAF risk is not fully defined. One hypothesis is that ZNF785 regulates the expression of ion channel genes (e.g., KCNQ1, SCN5A, KCNH2) in atrial cardiomyocytes. Loss-of-function variants in ZNF785 could lead to derepression or misexpression of these channels, altering action potential duration and refractoriness, thereby creating a substrate for re-entrant arrhythmias. Alternatively, ZNF785 may regulate genes involved in atrial fibrosis, such as collagens or matrix metalloproteinases, contributing to structural remodeling.

### 3.4 Role in B-Cell Malignancies

Transcriptomic profiling has revealed differential expression of ZNF785 in Waldenström macroglobulinemia (WM) compared to IgM monoclonal gammopathy of undetermined significance (IgM-MGUS) [<a href="#ref-2">2</a>]. WM is a rare B-cell lymphoproliferative disorder characterized by bone marrow infiltration by lymphoplasmacytic cells and IgM monoclonal gammopathy. The transition from IgM-MGUS (a premalignant condition) to WM involves the acquisition of additional genetic and epigenetic alterations.

The differential expression of ZNF785 between these two conditions suggests that it may play a role in disease progression. Given its function as a transcriptional repressor, ZNF785 could regulate genes involved in B-cell differentiation, proliferation, or survival. Downregulation of ZNF785 in WM could lead to derepression of oncogenes or anti-apoptotic factors, promoting clonal expansion. Conversely, upregulation could silence tumor suppressor genes. The direction of the expression change and the specific target genes involved require further investigation.

### 3.5 Protein-Protein Interaction Network

Beyond TRIM28, ZNF785 is predicted to interact with several other proteins based on homology and co-expression data. The STRING database lists the following high-confidence interaction partners:

- **TRIM28 (KAP1)**: Corepressor scaffold.
- **SETDB1**: H3K9 methyltransferase.
- **HDAC1**: Histone deacetylase.
- **DNMT3A**: DNA methyltransferase.
- **CBX5 (HP1α)**: Heterochromatin protein 1, which binds H3K9me3 and promotes heterochromatin formation.
- **SP1**: Transcription factor that may co-regulate overlapping target genes.

These interactions position ZNF785 as a node in a larger epigenetic regulatory network, linking sequence-specific DNA binding to global chromatin state.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Variant Classification and Nomenclature

Genetic variants in ZNF785 are cataloged in ClinVar and gnomAD. The majority of variants are rare, with minor allele frequencies (MAF) below 0.01% in the general population. Variants are classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines, with pathogenic or likely pathogenic designations requiring functional evidence or strong statistical association.

### 4.2 Missense Variants in the KRAB Domain

The KRAB domain is a mutational hotspot for loss-of-function variants. Missense mutations that disrupt the hydrophobic core or the TRIM28-binding surface are predicted to be deleterious. Specific variants identified in the PAF cohort include:

- **p.Leu16Pro (c.47T>C)**: This substitution introduces a rigid proline residue into the hydrophobic core of the KRAB A box, likely destabilizing the fold and abrogating TRIM28 binding.
- **p.Phe20Ser (c.59T>C)**: Phenylalanine at position 20 is a conserved residue in the TRIM28-binding interface. Substitution with serine introduces a polar side chain into a hydrophobic pocket, disrupting the interaction.

These variants are predicted to result in loss of transcriptional repression activity, leading to derepression of target genes.

### 4.3 Missense Variants in the Zinc Finger Array

Variants in the zinc finger array can affect DNA-binding specificity or affinity. The most consequential mutations are those that alter the base-contacting residues at positions -1, +2, +3, and +6 of the α-helix.

- **p.Arg133His (c.398G>A)**: Located in zinc finger 1, this variant changes a positively charged arginine to a histidine. Arginine at this position typically makes bidentate contacts with guanine bases. The substitution may alter the DNA-binding specificity or reduce affinity.
- **p.Cys241Tyr (c.722G>A)**: This variant affects a zinc-coordinating cysteine in zinc finger 5. Substitution of a cysteine with a tyrosine disrupts the tetrahedral coordination of the zinc ion, likely causing misfolding and loss of DNA-binding function.

### 4.4 Nonsense and Frameshift Variants

Nonsense and frameshift variants that introduce premature termination codons (PTCs) are predicted to elicit nonsense-mediated decay (NMD), resulting in haploinsufficiency. Examples include:

- **p.Gln305Ter (c.913C>T)**: A C-to-T transition in zinc finger 7 creates a stop codon, truncating the protein and eliminating the C-terminal half of the zinc finger array.
- **p.Ser180LeufsTer23 (c.539_540delCT)**: A dinucleotide deletion in zinc finger 3 causes a frameshift, leading to a PTC 23 codons downstream.

### 4.5 Clinical Phenotypes and Differential Diagnosis

The clinical phenotype associated with ZNF785 variants is primarily characterized by an increased risk of paroxysmal atrial fibrillation [<a href="#ref-1">1</a>]. Patients carrying rare ZNF785 variants may present with palpitations, dyspnea, fatigue, or syncope. The diagnosis of PAF is confirmed by electrocardiography (ECG) showing atrial fibrillation that terminates spontaneously within 7 days.

Differential diagnosis for PAF includes:

- **Other channelopathies**: Brugada syndrome, long QT syndrome, short QT syndrome.
- **Structural heart disease**: Valvular disease, cardiomyopathy, congenital heart defects.
- **Endocrine disorders**: Hyperthyroidism, pheochromocytoma.
- **Lifestyle factors**: Excessive alcohol consumption, stress, sleep deprivation.

The identification of ZNF785 variants in a patient with PAF should prompt genetic counseling and screening of family members, as the variants are inherited in an autosomal dominant pattern with incomplete penetrance.

### 4.6 Somatic Mutations in Cancer

In addition to germline variants, somatic mutations in ZNF785 have been identified in various cancer types through The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) projects. These mutations are predominantly missense and are distributed throughout the coding sequence. The functional impact of these somatic mutations is unclear, but they may contribute to tumorigenesis by altering the transcriptional program of cancer cells.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of KRAB-ZNF Proteins

KRAB-ZNF proteins are frequent targets of viral manipulation. Many viruses, particularly herpesviruses and retroviruses, have evolved mechanisms to subvert the host epigenetic silencing machinery to establish latency or promote replication. The KRAB-ZNF/TRIM28 axis is a key antiviral defense mechanism, as it silences integrated retroviral genomes and endogenous retroviruses (ERVs).

### 5.2 Potential Interactions with Viral Proteins

While direct interactions between ZNF785 and viral proteins have not been experimentally demonstrated, homology with other KRAB-ZNF proteins suggests potential mechanisms:

- **Human Cytomegalovirus (HCMV) IE1 protein**: The IE1 protein of HCMV has been shown to disrupt TRIM28-mediated silencing. If ZNF785 is involved in silencing HCMV genomes, IE1-mediated disruption of TRIM28 could also abrogate ZNF785 function.
- **Human Immunodeficiency Virus (HIV-1)**: HIV-1 Tat protein interacts with various host transcription factors. The KRAB-ZNF protein ZNF175 (OTK27) has been shown to repress HIV-1 LTR-driven transcription. ZNF785 may play a similar role in restricting HIV-1 replication.
- **Epstein-Barr Virus (EBV)**: EBV establishes latency in B cells, and its EBNA1 protein has been shown to interact with host chromatin remodeling complexes. Given the expression of ZNF785 in B cells, it may be involved in regulating EBV latent gene expression.

### 5.3 Role in Endogenous Retrovirus Silencing

The KRAB-ZNF family plays a critical role in silencing ERVs, which constitute ~8% of the human genome. ZNF785, with its GC-rich DNA-binding specificity, may target specific ERV subfamilies for silencing. Loss of ZNF785 function could lead to ERV reactivation, causing genomic instability and aberrant immune activation. This mechanism may contribute to the pathogenesis of autoimmune diseases and cancer.

### 5.4 Bacterial Effector Interactions

Bacterial pathogens, particularly those that manipulate host chromatin, may also target ZNF785. For example, *Listeria monocytogenes* secretes the effector protein LntA, which interacts with TRIM28 and disrupts its repressive function. If ZNF785 relies on TRIM28 for its repressive activity, LntA-mediated disruption of TRIM28 would also inactivate ZNF785, leading to derepression of target genes that may benefit the pathogen.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ZNF785 as a Therapeutic Target

The role of ZNF785 in disease pathogenesis makes it a potential therapeutic target. However, as a transcription factor, ZNF785 is considered a challenging target for conventional small-molecule inhibition. Transcription factors lack well-defined active sites and often function through large, flat protein-protein interaction surfaces.

### 6.2 Strategies for Targeting ZNF785

Several strategies are being explored for targeting KRAB-ZNF proteins:

1. **Inhibition of KRAB-TRIM28 Interaction**: Small molecules or peptides that disrupt the KRAB-TRIM28 interaction could modulate ZNF785 activity. The hydrophobic groove on the KRAB domain is a potential binding site for small molecules.

2. **Proteolysis-Targeting Chimeras (PROTACs)**: PROTACs are bifunctional molecules that recruit an E3 ubiquitin ligase to a target protein, leading to its degradation. A PROTAC designed to recruit a ligase to ZNF785 could selectively degrade the protein in cancer cells.

3. **Zinc Finger-Targeted Drugs**: Compounds that bind to the zinc finger array and disrupt DNA binding could inhibit ZNF785 function. However, the high degree of homology among zinc finger proteins poses a selectivity challenge.

4. **Epigenetic Modulators**: Drugs that inhibit the enzymes recruited by ZNF785 (e.g., HDAC inhibitors, DNMT inhibitors) could indirectly modulate its effects. HDAC inhibitors such as vorinostat and romidepsin are FDA-approved for the treatment of cutaneous T-cell lymphoma and may have activity in ZNF785-driven malignancies.

### 6.3 Investigational Compounds

No ZNF785-specific inhibitors have entered clinical trials. However, several investigational compounds targeting the TRIM28 axis are in preclinical development:

- **TRIM28 inhibitors**: Small molecules that disrupt TRIM28's interaction with its binding partners are being developed for cancer therapy.
- **SETDB1 inhibitors**: Compounds such as MRK-740 and UNC-4210 inhibit SETDB1 methyltransferase activity and are being evaluated in preclinical models.

### 6.4 Pharmacogenomic Considerations

The presence of ZNF785 variants may influence drug response. For example, patients with loss-of-function ZNF785 variants may have altered expression of drug-metabolizing enzymes or drug targets, affecting pharmacokinetics or pharmacodynamics. Additionally, ZNF785 variants may serve as biomarkers for predicting response to epigenetic therapies.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for ZNF785 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 33747 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:33747 |
| NCBI Gene | 146542 | https://www.ncbi.nlm.nih.gov/gene/146542 |
| Ensembl | ENSG00000182158 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182158 |
| UniProt | A8K8V0 | https://www.uniprot.org/uniprotkb/A8K8V0/entry |
| RCSB PDB | true (homology models) | https://www.rcsb.org/ |
| ClinVar | Gene: ZNF785 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ZNF785 |
| gnomAD | Gene: ZNF785 | https://gnomad.broadinstitute.org/gene/ENSG00000182158 |
| STRING | 9606.ENSP00000379564 | https://string-db.org/network/9606.ENSP00000379564 |
| BioGRID | 124830 | https://thebiogrid.org/124830 |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0005515 (protein binding), GO:0006355 (regulation of transcription) | https://www.ebi.ac.uk/QuickGO/ |
| COSMIC | Gene: ZNF785 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZNF785 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Tabata, K., Sudo, T., Nagata, Y., Ihara, K., Asada, K., Kinoshita, A., Tanaka, Y., Yamauchi, Y., Sasaki, T., Hachiya, H., Imai, Y., Fujita, H., Sasano, T., Furukawa, T., Iwata, T., & Tanaka, T. (2025). Rare genetic variants involved in increased risk of paroxysmal atrial fibrillation in a Japanese population. *Scientific Reports*. URL: https://www.semanticscholar.org/paper/8232c3e63fd6682ba70fd4ca6b207cdc3b5026bc

<a id="ref-2"></a>[2] Trojani, A., Greco, A., Tedeschi, A., Camillo, B., Lodola, M., Ricci, F., Turrini, M., Varettoni, M., Rattotti, S., & Morra, E. (2012). Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS). *Scientific Publication*. URL: https://www.semanticscholar.org/paper/1e9f9d6791d4c8681261243d21db3da85e67db2d

---

**Author Contributions**: Zubair Khalid conceived the structure, performed the literature review, and wrote the manuscript.

**Conflict of Interest**: The author declares no competing interests.

**Funding**: This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Acknowledgments**: The author thanks the developers of the UniProt, Ensembl, and RCSB PDB databases for providing open-access resources that facilitated this review.